At a glance

ClinicalIndex Comparison Record

N/ACompleted· 400 enrolled

Drug / intervention

5ARI or AB or Combination Therapy (5ARI + AB)drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01390870

NCT01390870N/ACompleted

Compare CT.gov

Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence

GlaxoSmithKline·observational·Posted Jul 11, 2011·Updated May 17, 2017

In Brief

An observational study evaluating 5ARI or AB or Combination Therapy (5ARI + AB) for Prostatic Hyperplasia. Completed, enrolled 400 participants.

Detailed Summary

Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be evaluated. The researchers believe that the majority of participants will report that they are compliant with therapy. The data source is a cross-sectional patient survey administered at one time point.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsProstatic Hyperplasia

Countries--

Collaborators--

Timeline

N/ACompletedFinished

200920102011201220132014201520162017201820192020202120222023202420252026

Enrollment StartMay 2009

Primary CompletionSep 2010

First PostedJul 2011

TodayJul 2026

First PostedJul 11, 2011

Enrollment StartMay 1, 2009

Primary CompletionSep 1, 2010

TodayJul 2, 2026

Enrollment to primary: 1.3 yearsPosted 15.0 years ago

Interventions

5ARI or AB or Combination Therapy (5ARI + AB)drug

5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin